Search
-
GSK launches first call for proposals for research in to non-communicable diseases in sub-Saharan Africa
Media
GSK launched first call for proposals for its Africa NCD Open Lab, to support much-needed scientific research into NCDs in Africa.
https://www.gsk.com/en-gb/media/press-releases/gsk-launches-first-call-for-proposals-for-research-in-to-non-communicable-diseases-in-sub-saharan-africa/
First published: 14 November 2014
-
Regulatory update on transaction with Novartis
Media
GSK providing AN update relating to the major three-part transaction with Novartis AG (the Original Announcement).
https://www.gsk.com/en-gb/media/press-releases/regulatory-update-on-transaction-with-novartis/
First published: 26 November 2014
-
GSK announces US regulatory submission seeking expanded indication for FluLaval® Quadrivalent (Influenza Vaccine) for infants 6 mos+
Media
This vaccine is currently approved for active immunisation against influenza A subtype viruses and type B viruses
https://www.gsk.com/en-gb/media/press-releases/gsk-announces-us-regulatory-submission-seeking-expanded-indication-for-flulaval-quadrivalent-influenza-vaccine-for-infants-6-mosplus/
First published: 02 February 2016
-
GSK’s global HIV business ViiV Healthcare completes transactions to acquire Bristol-Myers Squibb’s R&D HIV assets
Media
ViiV Healthcare has completed two previously announced transactions with Bristol-Myers Squibb
https://www.gsk.com/en-gb/media/press-releases/gsk-s-global-hiv-business-viiv-healthcare-completes-transactions-to-acquire-bristol-myers-squibb-s-rd-hiv-assets/
First published: 22 February 2016
-
Results announcement for the first quarter 2015
Media
GSK reports Q1 sales of £5.6 billion; Core EPS of 17.3p (-16%) CER
https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-first-quarter-2015/
First published: 06 May 2015
-
GSK submits US regulatory filing of Arnuity Ellipta in children with asthma
Media
The sNDA is seeking approval for a dose of 50mcg once-daily, delivered using the Ellipta inhaler in this group of patients.
https://www.gsk.com/en-gb/media/press-releases/gsk-submits-us-regulatory-filing-of-arnuity-ellipta-in-children-with-asthma/
First published: 24 July 2017
-
GSK’s Synflorix™ receives CHMP positive opinion for major label extension
Media
GSK announced that the CHMP of EMA has issued a positive opinion for the expansion of the SynflorixTM European label
https://www.gsk.com/en-gb/media/press-releases/gsk-s-synflorix-receives-chmp-positive-opinion-for-major-label-extension/
First published: 27 July 2015
-
GSK’s Nucala® (mepolizumab) receives approval from US FDA
Media
First anti-IL5 treatment for adults and adolescents with severe asthma with an eosinophilic phenotype
https://www.gsk.com/en-gb/media/press-releases/gsk-s-nucala-mepolizumab-receives-approval-from-us-fda/
First published: 04 November 2015
-
GSK and Theravance announce initiation of phase III programme with fixed dose triple combination treatment FF/UMEC/VI in patients with COPD
Media
GSK and Theravance, Inc. today announced the start of a global phase III study, known as IMPACT.
https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-initiation-of-phase-iii-programme-with-fixed-dose-triple-combination-treatment-ffumecvi-in-patients-with-copd/
First published: 16 July 2014
-
GSK announces overall survival results from phase III BREAK-3 study of Tafinlar® (dabrafenib) in patients with BRAF V600E-mutant metastatic melanoma
Media
GSK updated results for Tafinlar® from a planned analysis of the phase III BREAK-3 study in 250 patients with BRAFV600E metastatic melanoma.
https://www.gsk.com/en-gb/media/press-releases/gsk-announces-overall-survival-results-from-phase-iii-break-3-study-of-tafinlar-dabrafenib-in-patients-with-braf-v600e-mutant-metastatic-melanoma/
First published: 29 September 2014